Waiting
Traitement de la connexion…

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Immunology and Infection / In Vitro Methods for Comparing Target Binding and …
JoVE Journal
Immunology and Infection

Un abonnement à JoVE est nécessaire pour afficher ce contenu. Connectez-vous ou commencez votre essai gratuit.

JoVE Journal Immunology and Infection
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies
 

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Article DOI: 10.3791/55542-v • 07:25 min • May 4th, 2017
May 4th, 2017 •
1,2, 1, 3, 4,5, 6
1Unit for Development and Research in Bioprocesses Unit (UDIBI), National School of Biological Sciences, National Polytechnic Institute (IPN), University of Mexico (UNAM), 2School of Chemistry, National Autonomous University of Mexico (UNAM), 3Graduate Program in Chemical Sciences, National Autonomous University of Mexico (UNAM), 4Unit for Development Research and Medical Innovation in Biotechnology (UDIMEB), National School of Biological Sciences, National Polytechnic Institute (IPN), 5Department of Immunology, National Scool of Biological Sciences, National Polytechnic Institute (IPN), 6Department of Pharmacology and Unit of Translational Biomedicine (CMN 20 de noviembre), School of Medicine, National Autonomous University of Mexico (UNAM)

Chapitres

résumé
Automatic Translation

This protocol describes the in vitro comparison of two key functional characteristics of rituximab: target binding and complement-dependent cytotoxicity (CDC) induction. The methods were employed for a side-to-side comparison between reference rituximab and a rituximab biosimilar. These assays can be employed during biosimilar development or as a quality control in their production.

Tags

In Vitro Methods Therapeutic Antibodies Target Binding CDC Induction Biosimilarity Analysis Functional Differences Quality Control Production Edith Gonz Monoclonal Antibodies Cancers Biosimilar MAbs Drug Accessibility Therapy-associated Costs Rituximab Daudi Cells Structural Regions Clinical Effect Physicochemical Differences
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter